Category: Prohost Letters
Prohost Letter #460 ~ Treating IgA Nephropathy
Prohost Letter #460 Treating IgA Nephropathy Immunoglobulin A ( IgA ), the antibody of the immune system known to fight infections, can itself cause two important diseases. It can attack the body causing autoimmune diseases and can build up glomeruli...
Read More
June 1, 2024
0
Prohost Letter #461 ~ Preventing HIV Infection and Treating Primary Biliary Cholangitis
Prohost Letter #461 Preventing HIV Infection and Treating Primary Biliary Cholangitis Gilead Sciences Gilead Sciences’ ( GILD ) stock price has been paralyzed for more than three consecutive years. The long paralysis of Gilead reminds us of Amgen Therapeutics whose...
Read More
August 21, 2024
0
Shorting Biotech Firms with Solid Fundamentals
Prohost Comprehensive Letter #451 Shorting Biotech Firms with Solid Fundamentals Unfair shorting of promising stocks seems to have become the norm during the harsh circumstances that not only the United States but several other countries have been living under for...
Read More
July 19, 2022
0
Prohost Letter #461 ~ Preventing HIV Infection and Treating Primary Biliary Cholangitis
Prohost Letter #461 Preventing HIV Infection and Treating Primary Biliary Cholangitis Gilead Sciences Gilead Sciences’ ( GILD ) stock price has been paralyzed for more than three consecutive years. The long paralysis of Gilead reminds us of Amgen Therapeutics whose...
Read More
August 21, 2024
0
Treating Untreatable Disease - NASH
Prohost Letter #452 Treating Untreatable Disease - NASH Non Alcoholic Steatohepatitis The efforts spent on treating Non Alcoholic Steatohepatitis (NASH) have reached a promising stage where clinical trial data from the clinical-stage and revenue-generating biotech firms have demonstrated capability of...
Read More
October 13, 2022
0
Gilead Sciences - Still Way Undervalued
Prohost Letter #453 Gilead Sciences Still Way UNDERVALUED Finally, many analysts who happened to downgrade Gilead Science’s ( GILD ) stock for years are upgrading it. Demonstrating time and time again its scientific genius in saving millions of people from...
Read More
December 29, 2022
0
Prohost Letter #455
Prohost Letter #455 Introduction Our Prohost Letter disappeared for six months. Several reasons dictated our decision to temporarily halt its publication. The major reason was the devastating visit of COVID-19. COVID -19 paralyzed many countries. It devastated the world’s economy,...
Read More
June 28, 2023
0
Treatments for Untreatable Diseases
Prohost Letter #456 Treatments for Untreatable Diseases The revolution in biotechnology is not meant to offer just improvements on approved and marketed drugs. We are witnessing novel investigational products demonstrating safety, efficacy, statistically significant and clinically meaningful results in treating...
Read More
July 16, 2023
0
Discovering The Root Causes of Diseases
Prohost Letter #457 Discovering The Root Causes of Diseases Biotech firms with solid scientific fundamentals are racing towards unveiling the root-causes of various diseases that have yet to be completely unveiled. Knowing the root causes of diseases enabled some...
Read More
September 15, 2023
0
Prohost Letter #458 ~ Obesity
Prohost Letter #458 ~ Obesity Finally, obesity is being recognized as a severe sickness. Indeed, obesity is several devastating diseases, which include cardiovascular diseases, high blood pressure, Type 2 diabetes, cancers, sleep apnea, breathing problems, and more. Many studies demonstrated...
Read More
December 18, 2023
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)